This is the authors' abstract. We don't add key points for this paper.
Although these innovations offer renewed hope in the fight against obesity, they also pose challenges. Barriers to widespread adoption and access still exist, especially in manufacturing peptide therapeutics, which need significant investments in production infrastructure to reach more than hundreds of millions of patients worldwide.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Søren Østergaard (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: